TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32348101
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with rivaroxaban for six months and ECS for 12 months
Study: 36501092
Drug: GTC+CCA (620
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTC+CCA (620 mg GTC, 373 mg CCA, and 119 mg caffeine/day) for three weeks
Study: 36501092
Drug: PLA (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (0 mg GTC, 0 mg CCA, and 119 mg caffeine/day) for three weeks
Study: 32916291
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative strategy (medical therapy)
Study: 34856913
Drug: Topical ozonated
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozonated olive oil lotion
Study: 33253864
Drug: Topical GM-CSF
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GM-CSF and miltefosine (G + M)
Study: 33253864
Drug: Parenteral meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral meglumine antimoniate (MA)
Study: 32616150
Drug: Baroreflex Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex Activation Therapy (BAT) plus optimal medical management
Study: 35869690
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg/m2/day (n = 32)
Study: 35869690
Drug: Cyclosporine (CYC)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CYC) 5 mg/kg/day (n = 34)
Study: 33740389
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg GSH per day
Study: 33230526
Drug: CT-P13 s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 s.c. 120 mg biweekly until W28
Study: 33230526
Drug: CT-P13 i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 i.v. 3 mg/kg every 8 weeks until W22
Study: 32297162
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus over 30 minutes, followed by 1 mg/kg/h continuous infusion for 6 hours post-surgery)
Study: 35089354
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication regimens that stimulate type 2 and 4 angiotensin II receptors
Study: 35089354
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication regimens that inhibit type 2 and 4 angiotensin II receptors
Study: 35089354
Drug: Stimulating-only antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulating-only antihypertensive medications
Study: 35089354
Drug: Inhibiting-only antihypertensive
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibiting-only antihypertensive medications
Study: 32498113
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation empagliflozin tablet under fasting condition
Study: 32498113
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation Jardiance under fasting condition
Study: 32498113
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation empagliflozin tablet under fed condition
Study: 32498113
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation Jardiance under fed condition
Study: 34363293
Drug: Intrapartum oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapartum oxytocin administration
Study: 36114623
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (40 ppm) during DL,NO manoeuvre
Study: 33559611
Drug: C‐phycocyanin (C‐PC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐phycocyanin (C‐PC) with small-molecule additives
Study: 36231728
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) for 30 min/day for 4 weeks
Study: 32639649
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of Metformin
Study: 32579298
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of rosuvastatin/metformin sustained-release (10/1000 mg) in fasted and fed states
Study: 32579298
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of 10 mg rosuvastatin and 1000 mg metformin sustained release in the fed state
Study: 32579298
Drug: Effect of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of food on pharmacokinetics
Study: 33971141
Drug: Apatinib 750
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 750 mg orally once daily
Study: 33080623
Drug: Isatuximab monotherapy
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab monotherapy (20 mg/kg on days 1, 8, 15, and 22 of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles)
Study: 33080623
Drug: Isatuximab combined
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab combined with dexamethasone (40 mg/d, 20 mg/d for patients aged ≥75 years, once weekly)
Study: 36256584
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion (RME) activated twice daily
Study: 32683790
Drug: l-citrulline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-citrulline (3 g) daily for 2 months
Study: 32683790
Drug: microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: microcrystalline cellulose (placebo) daily for 2 months
Study: 32779919
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisolone per day for 6 weeks
Study: 34793405
Drug: Naltrexone (endogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (endogenous opioid antagonist)
Study: 32616263
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg VC
Study: 32616263
Drug: 1,000 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/kg VC
Study: 33451596
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches (hydrocolloid)
Study: 33518471
Drug: Topical xylometazoline
Normalized name: XYLOMETAZOLINE
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical xylometazoline (0.1%)
Study: 33518471
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline nasal spray, 0.74% w/v isotonic solution)
Study: 35346603
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid + ezetimibe fixed-dose combination
Study: 32379667
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care and treatment (Control)
Study: 34880010
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL convalescent plasma (CP) daily for up to 10 days (until virus negative in blood) plus standard care
Study: 616497045
Drug: Eggshell calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eggshell calcium (300 mg/d)
Study: 616497045
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (300 mg/d)
Study: 33128303
Drug: Aspartame (ASP)
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (ASP) at a dose of 40 mg/kg/day
Study: 33128303
Drug: Caffeine at
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine at a dose of 80 mg/kg/day
Study: 33128303
Drug: Aspartame (ASP)
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (ASP) and caffeine combined at previous doses
Study: 34015659
Drug: Sodium selenate
Normalized name: Sodium Selenate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium selenate (12.5 μg Se kg−1 soil)
Study: 33118519
Drug: Medical ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical ozone oil (1 mL, applied locally 3 times per day for 12 weeks)
Study: 33118519
Drug: Urea ointment
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea ointment (10% urea, 2 g, applied locally 3 times per day for 12 weeks)
Study: 34011342
Drug: Preoperative LMWH
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative LMWH administration (4000 IU per day)
Study: 34011342
Drug: Postoperative LMWH
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative LMWH administration (4000 IU per day)
Study: 32147037
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) plus exercise
Study: 32147037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ultrasound (US), Transcutaneous Nerve Stimulation (TENS) and exercise
Study: 33015809
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration (MED)
Study: 33781915
Drug: Pabinafusp alfa
Normalized name: Pabinafusp alfa
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pabinafusp alfa at 1.0 mg/kg/week
Study: 33781915
Drug: Pabinafusp alfa
Normalized name: Pabinafusp alfa
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pabinafusp alfa at 2.0 mg/kg/week
Study: 33781915
Drug: Pabinafusp alfa
Normalized name: Pabinafusp alfa
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pabinafusp alfa at 4.0 mg/kg/week
Study: 33343577
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccines (QIVs)
Study: 35361657
Drug: Single pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single pill containing quadruple combination of quarter doses of blood pressure medicines
Study: 35361657
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose irbesartan
Study: 33124749
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake of 180 mg shortly before surgery (intervention group)
Study: 36402670
Drug: Volanesorsen 300
Normalized name: Volanesorsen
DrugBank: Volanesorsen (DB15067)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Volanesorsen 300 mg weekly subcutaneous injection
Study: 33052103
Drug: Two‐compound gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two‐compound gel once daily for 28 weeks
Study: 33052103
Drug: Calcipotriol scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol scalp solution twice daily for 28 weeks
Study: 36478762
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulants (DOAC) within 48 hours of minor or moderate stroke, or at day 6-7 following major stroke.
Study: 36478762
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of direct oral anticoagulants (DOAC) after day 3-4 following minor stroke, after day 6-7 following moderate stroke and after day 12-14 following major stroke.
Study: 36478762
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulants (DOAC)
Study: 36478762
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of direct oral anticoagulants (DOAC)
Study: 34023312
Drug: 1-step diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-step diagnostic testing protocol (75 g, 2-hour oral glucose tolerance test)
Study: 34023312
Drug: 2-step screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-step screening protocol (50 g, 1-hour glucose challenge followed by 100 g, 3-hour oral glucose tolerance test)
Study: 32020414
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus two HIIT sessions (MET+EX)
Study: 34721385
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) in addition to pharmacotherapy (SLIT+PT)
Study: 34721385
Drug: Pharmacotherapy (PT)
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (PT) alone
Study: 35213393
Drug: Green Tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Tea Extract (GTE) standardized to 150 mg of EGCG b.i.d. for 3 years
Study: 32014060
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone (4 doses of 1 mL of 40 mg/mL over 1 week, every 2 days)
Study: 32014060
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 mg/kg/day, maximal dose 60 mg/day for 5 days)
Study: 35673509
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (N.S) oil supplement, 2000 mg/d for 8 weeks
Study: 32191366
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention (adequate dose participants)
Study: 32191366
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (adequate dose participants)
Study: 32926410
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) and Control group
Study: 33305900
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.3 mg/kg)
Study: 35502922
Drug: Fostemsavir plus
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir plus optimized background therapy (OBT)
Study: 35502922
Drug: Optimized background
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background therapy (OBT)
Study: 35694933
Drug: Mevidalen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen (30 mg)
Study: 35694933
Drug: Mevidalen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen (10 mg)
Study: 34664427
Drug: Mevidalen (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen (75 mg)
Study: 33674869
Drug: Targeted azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Targeted azithromycin treatment (thrice over the following year)
Study: 33674869
Drug: Delayed azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed azithromycin treatment
Study: 33674869
Drug: Targeted azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Targeted azithromycin treatment
Study: 35452830
Drug: CRRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRRT with topical citrate + low-dose LMW heparin-calcium anticoagulation
Study: 35452830
Drug: CRRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRRT with low molecular weight (LMW) heparin-calcium anticoagulation
Study: 35775311
Drug: Adjunctive diode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive diode laser application (90s, 810nm, 2.5W, 50Hz, 10ms)
Study: 35775311
Drug: Non-activated adjunctive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-activated adjunctive diode laser
Study: 35775311
Drug: Adjunctive diode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive diode laser application
Study: 33137378
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 15 mg daily for 6 months
Study: 33957651
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg oral, 36 hours before surgery)
Study: 33957651
Drug: Misoprostol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (400 micrograms buccal, 3 hours before surgery)
Study: 32525882
Drug: Care bundle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care bundle interventions including chest X-ray, CURB-65 severity score, lower respiratory tract samples, and antibiotics within 8 hours from admission.
Study: 36115950
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of iron (Stratum 1)
Study: 36115950
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d of iron (Stratum 1)
Study: 36115950
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d of iron (Stratum 2)
Study: 36115950
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of iron (Stratum 2)
Study: 34710557
Drug: Difamilast ointment
Normalized name: Difamilast
DrugBank: Difamilast (DB14987)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Difamilast ointment 1%
Study: 32890575
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR sublingual tablet
Study: 35668500
Drug: Curcumin-piperine co-supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin-piperine co-supplementation (500 mg curcumin + 5 mg piperine, 2 capsules daily for 14 days)
Study: 35668500
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules daily for 14 days)
Study: 34996756
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg orally once daily for 30 days
Study: 32678954
Drug: Non-surgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical debridement and glycine powder (G)
Study: 35191210
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate (200 mg equivalent of isavuconazole) administered orally or intravenously once daily for 16 days with a loading regimen every 8 hours for the first 48 hours
Study: 35191210
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate (100 mg, 200 mg, and 400 mg equivalent of isavuconazole) administered orally or intravenously (single ascending dose)
Study: 33238198
Drug: aPDT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPDT + oral hygiene behavior (OHB)
Study: 33238198
Drug: Lingual scraper
Normalized name: Nitroglycerin Lingual Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingual scraper + oral hygiene behavior (OHB)
Study: 33552050
Drug: Novel non-replacement
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel non-replacement therapies (including emicizumab)
Study: 36178679
Drug: Twice-weekly membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly membrane sweeping
Study: 36178679
Drug: Once-weekly membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly membrane sweeping
Study: 37042545
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg zolmitriptan
Study: 32162796
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oncologist training and patient communication aid
Study: 34463409
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg, 25 mg)
Study: 32028395
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and antimicrobial photodynamic therapy (PACT)
Study: 33104452
Drug: Voice bubbling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice bubbling therapy (VBT)
Study: 34634254
Drug: Single-dose HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose HPV vaccine
Study: 34634254
Drug: Two-dose HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose HPV vaccine
Study: 34634254
Drug: Three-dose HPV
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose HPV vaccine
Study: 32739466
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg/d plus 5 mL placebo syrup every 12 h
Study: 32739466
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of lavender-dodder herbal syrup every 12 h plus placebo tablets once daily
Study: 35729519
Drug: Ethinyl Estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl Estradiol (EE) starting at 11 years old with Growth Hormone (GH)
Study: 35729519
Drug: Ethinyl Estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl Estradiol (EE) starting at 13 years old with Growth Hormone (GH)